Nuclear factor-κB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia

Roger K. Strair, Mecide Gharibo, Dale Schaar, Arnold Rubin, Jonathan Harrison, Joseph Aisner, Hsin Ching Lin, Yong Lin, Lauri Goodell, Monika Anand, Binaifer Balsara, Liesel Dudek, Arnold Rabson, Daniel J. Medina

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Purpose: Nuclear factor-κB (NF-κB) is constitutively expressed in many acute myelogenous leukemia (AML) cells and AML stem cells. Ex vivo treatment of AML cells with inhibitors of NF-κB results in diminished AML cell survival and enhances the cytotoxic effects of chemotherapeutic agents. The purpose of this study was to determine if standard anti-inflammatory agents modulate AML cell nuclear NF-κB when administered in conjunction with induction chemotherapy. Experimental Design: Patients with newly diagnosed AML were treated with dexamethasone, choline magnesium trisalicylate, or both for 24 hours prior to and 24 hours following initiation of standard induction chemotherapy. AML cell nuclear NF-κB was measured at baseline, 24, and 48 hours. Results: Choline magnesium trisalicylate ± dexamethasone decreased nuclear NF-κB, whereas dexamethasone alone was associated with an increase in nuclear NF-κB in AML cells. Conclusions: These results show the feasibility of NF-κB modulation in conjunction with induction chemotherapy for patients with AML using inexpensive readily available medications. A follow-up study to determine the effects of NF-κB modulation on clinical end points is warranted.

Original languageEnglish (US)
Pages (from-to)7564-7568
Number of pages5
JournalClinical Cancer Research
Issue number22
StatePublished - Nov 15 2008

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Nuclear factor-κB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this